Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Tango has an exciting new opportunity to join our team as VP, Pharmaceutical Sciences. Reporting to our President of R&D, you will be responsible for Drug Metabolism and Pharmacokinetics, Preclinical Safety and Clinical Pharmacology. You will collaborate with colleagues in drug discovery and drug development to deliver successful IND and NDA submissions.
Your Role:
- You will be a recognized expert in clinical pharmacology with a track record of success in research and development
- Lead overall scientific, technical, and operational aspects of Pharmaceutical Science for R&D
- Recruit, develop and mentor talent as you build Pharmaceutical Sciences
- Collaborate with preclinical and clinical development teams to optimize study design and execution
- Represent Pharmaceutical Science as subject matter expert on R&D teams and governance boards
- Establish and maintain productive relationships with key internal business partners, consultants, and CROs
What You Bring:
- PhD or PharmD in clinical pharmacology, pharmacometrics, or related discipline with at least 15 years’ experience in the pharmaceutical and/or biotech industry
- Experience with small molecule drug development in oncology
- In-depth knowledge of drug metabolism, pharmacokinetics, biopharmaceutics, drug-drug interactions, and translational science
- Experience with health authority interactions
- Experience as lead or contributing clinical pharmacologist on a successful NDA submission
- Familiar with GLP, GCP, and ICH requirements
- Practical experience in modeling and simulation
- Highly motivated to work and collaborate in a fast-paced, high performing team
#LI-ONSITE
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Top Skills
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
